Inverse agonism at β-adrenergic receptors: Therapeutic implications

Expert Review of Neurotherapeutics

Volumn 2, Issue 2, 2002, Pages 261-269

  Gurdal, Hakan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

adrenergic receptors; G protein coupled receptors; Heart failure; Inverse agonist; Receptor models; Spotan activity; Therapeutic implications

Indexed keywords

ALPRENOLOL; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DICHLORISOPRENALINE; G PROTEIN COUPLED RECEPTOR; ICI 118552; LABETALOL; METOPROLOL; PARTIAL AGONIST; PINDOLOL; PROPRANOLOL; TIMOLOL; UNCLASSIFIED DRUG;

ALLOSTERISM; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; NONHUMAN; REVIEW; STOCHASTIC MODEL;

EID: 0036283866     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.2.261     Document Type: Review

References (68)

1. Single channel currents recorded from membrane of denervated frog muscle fibers
2. Functional reconstitution of the alpha 2-adrenergic receptor with guanine nucleotide regulatory proteins in phospholipid vesicles
3. The beta-adrenoceptor is precoupled to Gs in chicken erythrocyte membranes
4. Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins
5. Inverse agonism at G-protein coupled receptors: (Patho)physiological relevance and implications for drug discovery
6. Affinity and intrinsic activity in the theory of competitive inhibition. Part I. Problems and theory
7. A modification of receptor theory
8. Interaction at end-plate receptors between different choline derivatives
9. A ternary complex model explains the agonist-specific binding properties of the adenyl cyclase-coupled β-adrenergic receptor
10. βγ Subunits of guanine nucleotide-binding Proteins and regulation of spontaneous receptor activity: Thermodynamic model for the interaction between receptors and guanine nucleotide-binding protein subunits
11. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model
12. The cubic ternary complex receptor-occupancy model III. Resurrecting efficacy
13. A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor
14. Regulation of adenyl cyclase by G-proteins
15. Receptor to effector signaling through G-proteins: Roles for βγ dimers as well as α subunits
16. 2+ current in single rat ventricular cells
17. 2-adrenergic modulation of cardiac excitation-contraction coupling
18. Regulation of signaling in cardiac function and disease
19. Expression of two human beta-adrenergic receptors in Escherichia coli: Functional interaction with two forms of the stimulatory G-protein
20. Negative antagonists promote an inactive conformation of the β2-adrenergic receptor
21. Inverse agonist activity of β-adrenergic antagonists
22. Regulation of basal adenyl cyclase activity in neuroblastoma x glioma hybrid, NG108-15, cells transfected to express the human beta 2 adrenoceptor: Evidence for empty receptor stimulation of the adenyl cyclase cascade
23. Activation of calcium currents in cardiac myocytes by empty beta-adrenoceptors
24. Unoccupied beta-adrenoceptor-induced adenyl cyclase stimulation in turkey erythrocyte membranes
25. Inverse agonist activities of β-adrenoceptor antagonists in rat myocardium
26. Enhanced myocardial function in transgenic mice overexpressing the β2-adrenergic receptor
27. 2-adrenoceptor
28. 2-adrenoceptor on ligand affinity in transgenic mice
29. Ligand efficacy and affinity in an interacting 7TM receptor model
30. Constitutive activity of human β-adrenergic receptor in β1-receptor transgenic mice
31. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium
32. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium
33. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692
34. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor
35. Inverse, protean and ligand selective agonism: Matters of receptor conformation
36. Inverse agonist properties of dopaminergic antagonists at the D1a dopamine receptor: Uncoupling of the D 1a dopamine receptor from Gs protein
37. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxyttyptamine 2C receptors
38. Could the 5-HT1B receptor inverse agonism affect learning consolidation?
39. Antipsychoutic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects
40. Mutations in G-proteins and G-protein coupled receptors in endocrine disease
41. Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor
42. Receptors for PTH and PTHrP: Their biological importance and functional properties
43. Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic β2-adrenoceptor activation
44. 2-adrenergic receptor detected by Ban I-Adrbr-2
45. 2 adrenergic receptor locus
46. Pharmacogenetics of beta-1-and β-2-adrenergic receptors
47. 2-adrenergic receptor
48. The effects of agonist stimulation and β2-adrenergic receptor level on subcellular distribution of Gs alpha protein
49. Pharmacology of muscarinic receptor subtypes constitutively activated by G-proteins
50. Regulation of G-protein function: Implications for heart disease
51. Overexpression of c-src enhances β-adrenergic-induced cAMP accumulation
52. Mapping of a functional autoimmune epitope on the β-1 adrenergic receptor in patients with idiopatic dilated cardiomyopathy
53. Induction of a pharmacologically active clonotypic B-cell response directed to an immunogenic region of the human β-2 adrenergic receptor
54. β-2 adrenergic receptor antibodies in myasthenia gravis
55. High prevalence of antibodies against β 1-and β 2-adrenoceptors in patients with primary electrical cardiac abnormalities
56. Antipeptide antibodies sensitive to the active state of the β2-adrenergic receptor
57. 2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells
58. Inverse agonism and the regulation of receptor number
59. A sustained increase in beta-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy
60. Controlled trials with beta blockers in heart failure: Metoprolol as the prototype
61. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats
62. Second- and third-generation beta-blocking drugs in chronic heart failure
63. Current role of beta-adrenergic blockers in the treatment of chronic congestive heart failure
64. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
65. Beta-blocker use in systolic heart failure and dilated cadiomyopathy
66. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor
67. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy
68. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice